Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release.

1] Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan [2] Departments of Advanced Clinical Science and Therapeutics, Tokyo, Japan [3] Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan.
Laboratory Investigation (Impact Factor: 3.96). 09/2012; DOI: 10.1038/labinvest.2012.136
Source: PubMed

ABSTRACT The complex pathophysiological interactions between heart and kidney diseases are collectively known as cardiorenal syndrome. The renin-angiotensin system (RAS) may have a pivotal role in the development of cardiorenal syndrome. The aim of this study was to elucidate the RAS activity responsible for adverse post-infarction remodeling and prognosis in mice with renal failure. To establish the type IV cardiorenal syndrome model, 5/6 nephrectomy (NTX) was performed in a surgical procedure, followed by the induction of myocardial ischemia (MI) by a coronary artery ligation 4 weeks later. NTX and MI resulted in deteriorated left ventricular remodeling and RAS activation, which was improved by an aliskiren that appeared to be independent of renal function and blood pressure (BP). Moreover, MI induced in renin and angiotensinogen double-transgenic (Tg) mice showed comparable effects to MI plus NTX mice, including advanced ventricular remodeling and enhancement of RAS, oxidative stress, and monocytes chemoattractant protein (MCP)-1. Aliskiren suppressed these changes in the MI-induced Tg mice. In in vitro study, Nox2 expression was elevated by the stimulation of plasma from NTX mice in isolated neonatal cardiomyocytes. However, Nox2 upregulation was negated when we administered plasma from aliskiren-treated-NTX mice or isolated cardiomyocytes from AT1-deficient mice. Primary mononuclear cells also showed an upregulation in the expression of Nox2 and MCP-1 by stimulation with plasma from NTX mice. Our data suggest that renal disorder results in ventricular dysfunction and deteriorates remodeling after MI through excessive RAS activation. Moreover, renin inhibition improved the changes caused by cardiorenal syndrome.Laboratory Investigation advance online publication, 17 September 2012; doi:10.1038/labinvest.2012.136.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiorenal syndrome (CRS) is characterized as a syndrome involving both the cardiovascular system and kidneys. Due to its complexity and high mortality, it has becoming a significant burden and a universal clinical challenge to society worldwide. The mechanisms underlying CRS are potentially multifactorial, including hemodynamic alterations, neurohormonal activation, inflammation, oxidative stress, iron disorders, anaemia, and mineral metabolic derangements. Despite the understanding and awareness of CRS gaining attention, appropriate approaches to manage CRS remain deficient. Loop diuretic and thiazides, inhibition of the renin-angiotensin system, vitamin D receptor activation and dopamine and natriuretic peptides could potentially be helpful to improve the prognosis of CRS. Ultrafiltration might be an alternative therapeutic strategy for the loss of liquid. However, adenosine receptor antagonists appear to not be superior to furosemide in CRS treatment. Additional novel therapeutic approaches should be further explored.
    Life sciences 10/2013; · 2.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Nuclear factor-kappa B (NF-kappaB), which is activated by the inhibitor of NF-kappaB kinase (IKK), is involved in the progression of inflammatory disease. However, the effect of IKK inhibition on the progression of myocarditis is unknown. Objective: We examined the effect of IKK inhibition on the progression of myocarditis. Methods: Lewis rats were immunized with porcine cardiac myosin to induce experimental autoimmune myocarditis (EAM). We administered the IKK inhibitor (IMD-0354, 15mg/kg/day) or vehicle to EAM rats daily. Hearts were harvested 21 days after immunization. Results: Although the untreated EAM group showed increased heart weight to body weight ratio, severe myocardial damage, these changes were attenuated in the IKK inhibitor treated group. Moreover, IKK inhibitor administration significantly reduced NF-kappaB activation and mRNA expression of interferon-gamma (IFN-gamma), interleukin-2 (IL-2) and monocyte chemoattractant protein-1 (MCP-1) in myocardium compared with vehicle administration. In vitro study showed that the IKK inhibitor treatment inhibited T cell proliferation and Th1 cytokines production induced by myosin stimulation. Conclusion: The IKK inhibitor ameliorated EAM by suppressing inflammatory reactions via suppression of T-cell activation.
    AJP Heart and Circulatory Physiology 10/2013; · 4.01 Impact Factor


Available from